SpringWorks Therapeutics(SWTX) - 2024 Q2 - Quarterly Results

Exhibit 99.1 SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights ® – Achieved $40.2 million in OGSIVEO (nirogacestat) net product revenue in the second quarter – – Completed submission of NDA to the FDA for mirdametinib for the treatment of children and adults with NF1- PN – – Presented Phase 2b ReNeu trial results and additional analyses from Phase 3 DeFi trial at the 2024 ASCO Annual Meeting – – Initiated Phase 1a trial of SW-682 in patients with Hippo mut ...